Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction.
about
The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunctionPharmacogenetics of erectile dysfunction: navigating into uncharted watersSafety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.Clinical pearls in men's health.Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction.Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrateWhat to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience.Penile implants in the era of oral drug treatment for erectile dysfunction.Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.Treating erectile dysfunction when PDE5 inhibitors fail.Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness.Counseling patients about sexual issues.Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II.Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mgPatient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafilToward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunctionOptimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health.Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.Stem-cell therapy for erectile dysfunction.Mesenchymal stem cell-based gene therapy for erectile dysfunction.Effect of icariin in combination with daily sildenafil on penile atrophy and erectile dysfunction in a rat model of bilateral cavernous nerves injury.Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction.Rechallenge prior sildenafil nonresponders.Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction.Effects of sense tankyrase transfection on smooth muscle cells of corpus cavernosum in rat.Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction.Clinical predictive factors of sildenafil response: a penile hemodynamic study.Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients.Sexual Health and Overall Wellness (SHOW) survey in men and women in selected European and Middle Eastern countries.Advances in Stem Cell Therapy for Erectile DysfunctionLiving in the best of all worlds. Despite premises approximating the truth with meta-analyses
P2860
Q26747680-A79F29FF-F60A-4076-A08F-21F9F4EC1178Q28249515-D76636E9-3CE9-4D63-A9A7-51E8F78EED66Q33606588-AE609F5F-6788-464E-9A4B-008C5B864A16Q33951568-7EC6A2EB-7DA3-4631-9F2D-FB6812CEE4D6Q34569400-A5CEDE16-0FCE-44DC-B0D5-9E25ABC0BE6CQ34666969-C6D0E38D-FCD4-42BE-947E-25F756928787Q35606352-EC3C3AF4-395B-4868-99BB-6B8C06E6E978Q35871183-23CB23D2-7604-4568-9AF1-5D49C6EBE742Q36069701-FF405DF0-D4B4-4F09-8135-129E76A6E981Q36417687-0DDB25D0-7026-42ED-B7C4-7776C7F184A7Q36523906-E1E13AB0-60D1-4FF1-9B31-0635BF7D3FD3Q36634227-2610C734-A2AF-49A5-933E-A458E2FD5F22Q36808439-4E59EF4E-9759-4123-B136-355C62B1B017Q37165058-6A0193E6-2864-4033-AAD2-A86B489EE653Q37332804-401A9F90-AB4B-49B0-A590-C9D76EE51916Q37423701-76B4AED0-775E-476F-BCC8-0252C318D6FDQ37427312-3838E2B1-8D04-4011-9816-02F5E4218C52Q37886052-9899DA3C-1CCC-4703-BC64-8E0DB527428FQ37905563-7079102F-72EC-4C32-AB66-8DB298AC5EE4Q38148781-842AF9F3-9C45-4BEE-8059-B2B2B2AE8C72Q38738066-90919AC1-8446-45F9-B76D-8080B123A7E6Q38744754-CB80D76C-304E-49F2-9DBA-01E3B2527473Q42469987-86A420CF-977E-4EF3-BE57-E2C7CF299594Q44764465-83EAB84C-C61A-41BF-94FD-B59489C8917AQ45243766-E830801A-37F7-453A-A9AB-D94EC17672EFQ45855576-6E0ABACC-340C-4B95-9932-C996EB3C7B3AQ46255315-5CC8826D-2256-4AD7-A142-3B86BE37920FQ46437378-6924AD4D-29FB-4453-908A-E271A67FE69FQ46652301-1E1DE6AC-A571-48CC-9245-E8A847F14992Q46738583-8A620BD0-23D6-4159-9EE5-076521BCEA0BQ48264200-D23D6224-D61D-46D1-B5C8-B5B684F50DB3Q59048530-9FEAA8C7-DE52-414E-93F0-B41A6AEA468AQ59088386-9D595836-A849-4D6A-94F9-9A3B0B03FF7A
P2860
Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Achieving treatment optimizati ...... nts with erectile dysfunction.
@en
Achieving treatment optimization with sildenafil citrate
@nl
type
label
Achieving treatment optimizati ...... nts with erectile dysfunction.
@en
Achieving treatment optimization with sildenafil citrate
@nl
prefLabel
Achieving treatment optimizati ...... nts with erectile dysfunction.
@en
Achieving treatment optimization with sildenafil citrate
@nl
P2093
P1433
P1476
Achieving treatment optimizati ...... nts with erectile dysfunction.
@en
P2093
Ahmed Fawzy
Andre T Guay
Andrew R McCullough
Dimitrios Hatzichristou
James H Barada
P356
10.1016/S0090-4295(02)01688-6
P407
P433
P577
2002-09-01T00:00:00Z